We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
Sekisui Diagnostics UK Ltd.

Download Mobile App




Graphene-Based Biosensors Could Detect Sepsis Earlier in Critically Ill Patients

By LabMedica International staff writers
Posted on 09 Jun 2023
Print article
Image: Gii-Sens is the world`s first 3D Graphene foam electrode for biosensing (Photo courtesy of Integrated Graphene)
Image: Gii-Sens is the world`s first 3D Graphene foam electrode for biosensing (Photo courtesy of Integrated Graphene)

Lactate serves as a vital biomarker in managing hospitalized patients who are critically ill. A common complication in intensive care units, hyperlactatemia, can occur either due to insufficient oxygen supply to tissues or underlying conditions such as advanced liver disease. If left untreated, hyperlactatemia can escalate into lactate acidosis, a severe condition that can be life-threatening. Reliable real-time lactate detection, whether via single-point or continuous monitoring, has the potential to enhance patient outcomes in critical care and speed up the diagnosis of sepsis in critically ill individuals. Now, a new study has highlighted the significant potential of graphene-based biosensors for detecting elevated lactate levels.

The study by researchers at the University of Bath (Bath, UK) showed that using Integrated Graphene’s (Stirling, UK) Gii-Sens electrochemical sensor can enhance the diagnostic accuracy of hyperlactatemia. The Gii-Sens, a diagnostic biosensing electrode, outperforms conventional sensing materials by a factor of 10-100, enabling rapid, laboratory-quality testing at the point of need in a cost-effective manner. Gii-Sens electrochemical electrodes, produced using Integrated Graphene’s novel 3D graphene Gii, are disposable sensors designed for one-step assays without the need for pre-treatments.

“Lactate is a naturally occurring biomarker which everyone produces as a byproduct of exercising. For most people it is easily processed by the body and will cause no major harm, apart from a little cramp if you overexert yourself,” said Dr. Marco Caffio, Integrated Graphene’s Co-Founder and CSO. “However, for some critically ill patients and those with underlying conditions it can be a sign of a range of other issues, some of which, like sepsis, can be fatal. Having a robust way of monitoring lactate levels is important in ensuring the best possible outcomes for these patients. The findings of this study demonstrate Gii’s reliable performance and potential to save lives.”

Related Links:
University of Bath 
Integrated Graphene 

New
Platinum Member
Flu SARS-CoV-2 Combo Test
OSOM® Flu SARS-CoV-2 Combo Test
Magnetic Bead Separation Modules
MAG and HEATMAG
POCT Fluorescent Immunoassay Analyzer
FIA Go
New
Gold Member
Automatic ELISA Workstation
URANUS AE65

Print article

Channels

Clinical Chemistry

view channel
Image: The new ADLM guidance will help healthcare professionals navigate respiratory virus testing in a post-COVID world (Photo courtesy of 123RF)

New ADLM Guidance Provides Expert Recommendations on Clinical Testing For Respiratory Viral Infections

Respiratory tract infections, predominantly caused by viral pathogens, are a common reason for healthcare visits. Accurate and swift diagnosis of these infections is essential for optimal patient management.... Read more

Molecular Diagnostics

view channel
Image: The new tests seek to detect mutant DNA in blood samples, indicating the presence of cancer cells (Photo courtesy of Christian Stolte/Weill Cornell)

Advanced Liquid Biopsy Technology Detects Cancer Earlier Than Conventional Methods

Liquid biopsy technology has yet to fully deliver on its significant potential. Traditional methods have focused on a narrow range of cancer-associated mutations that are often present in such low quantities... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Industry

view channel
Image: For 46 years, Roche and Hitachi have collaborated to deliver innovative diagnostic solutions (Photo courtesy of Roche)

Roche and Hitachi High-Tech Extend 46-Year Partnership for Breakthroughs in Diagnostic Testing

Roche (Basel, Switzerland) and Hitachi High-Tech (Tokyo, Japan) have renewed their collaboration agreement, committing to a further 10 years of partnership. This extension brings together their long-standing... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.